Share Prices & Company Research

Market News

01 Feb 2021 | 13:23

Horizon Therapeutics to buy Viela Bio for $3.1bn

(Sharecast News) - US biotechnology company Horizon Therapeutics has agreed to buy Viela Bio for around $3.1bn. Under the terms of the deal, which is expected to close by the end of the first quarter, Horizon will pay $53.00 per share.

Horizon chairman, president and chief executive officer Tim Walbert said: "This acquisition represents a significant step forward in advancing our strategy - to expand our pipeline in order to accelerate our growth over the long term.

"Adding Viela's research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of Tepezza and Krystexxa to bolster our long-term growth trajectory. We intend to maximise the full potential of Viela's pipeline, including the pursuit of additional future indications."

Tepezza is indicated for the treatment of thyroid eye disease while Krystexxa is for chronic gout.

Horizon expects the transaction to reduce its adjusted earnings before interest, tax, depreciation and amortisation by approximately $140m in 2021, nearly all of which is attributable to increased research & development investment.

Maryland-based Viela is focused on the discovery, development and commercialisation of novel treatments for autoimmune and severe inflammatory diseases.

AstraZeneca announced separately it has agreed to divest its 26.7% stake in Viela as part of the deal.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.